4//SEC Filing
Eydelman Mikhail 4
Accession 0001649094-25-000012
CIK 0001649094other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 4:04 PM ET
Size
16.6 KB
Accession
0001649094-25-000012
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
Eydelman Mikhail
SVP, GEN COUNSEL & CORP SEC
Transactions
- Sale
Common Stock
2025-02-05$87.77/sh−571$50,115→ 32,651 total - Sale
Common Stock
2025-02-05$91.05/sh−1,784$162,437→ 28,477 total - Sale
Common Stock
2025-02-05$91.71/sh−255$23,386→ 28,222 total - Exercise/Conversion
Common Stock
2025-02-05$21.41/sh+5,000$107,050→ 33,222 total - Sale
Common Stock
2025-02-05$89.09/sh−635$56,571→ 32,016 total - Exercise/Conversion
Stock Option (right to buy)
2025-02-05−5,000→ 149,497 totalExercise: $21.41Exp: 2032-05-08→ Common Stock (5,000 underlying) - Sale
Common Stock
2025-02-05$89.95/sh−1,755$157,860→ 30,261 total
Footnotes (7)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.
- [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $87.405 to $88.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $88.52 to $89.385. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The price reported is a weighted-average price. The shares were sold at prices ranging from $89.53 to $90.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]The price reported is a weighted-average price. The shares were sold at prices ranging from $90.66 to $91.585. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]The price reported is a weighted-average price. The shares were sold at prices ranging from $91.69 to $91.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F7]1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
Documents
Issuer
Vaxcyte, Inc.
CIK 0001649094
Entity typeother
Related Parties
1- filerCIK 0001918033
Filing Metadata
- Form type
- 4
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 4:04 PM ET
- Size
- 16.6 KB